Ieagle123 at 16:30, 6 May 2026

2026-05-06T16:30:23Z

New page

{{Short description|Indian pharmaceutical company}}
{{Multiple issues|
{{Cleanup press release|1=article|date=April 2026}}
{{COI|date=April 2026}}
}}
{{Use dmy dates|date=March 2025}}
{{Use Indian English|date=March 2025}}
{{Infobox company
| name = Akums Drugs and Pharmaceuticals Limited
| logo = Akums Drugs and Pharmaceuticals.svg
| logo_caption = Company Logo
| image =
| image_size = 280
| image_caption =
| trading_name = Akums
| native_name =
| type = [[Public company|Public]]
| traded_as = {{NSE|AKUMS}} {{BSE|544222}}
| ISIN = {{ISIN|sl=n|pl=y|INE09XN01023}}
| industry = [[Pharmaceuticals]], [[Contract manufacturing organization|CDMO]] & [[Skincare]]
| founded = 2004 ; 21 years ago
| hq_location = [[Delhi]], [[India]]
| area_served = Worldwide
| key_people = Sandeep Jain<br>(Founder and Managing Director)
Sanjeev Jain<br>(Founder & Managing Director)
Arushi Jain<br>(Director)
| products = {{hlist|[[Pharmaceutical]]s| [[Nutraceutical]]s| [[Ayurvedic]]s| [[API]]s| [[Cosmetics|Cosmetic]]s | [[Dermatology]]s| [[Skincare]]s }}
| revenue = {{Increase}} {{INRConvert|1538.75|c|lk=on}} (FY24)
| assets = {{Increase}} {{INRConvert|2095.43|c|lk=on}} (FY24)
| num_employees = 10,000+ (2024)
| subsid = *Akumentis Healthcare Limited.
*Pure And Cure Healthcare Private Limited.
| website = {{URL|https://www.akums.in/}}
}}

'''Akums Drugs and Pharmaceuticals Limited (Akums Group)''' is an Indian pharmaceutical [[Contract manufacturing organization|Contract Development and Manufacturing Organization]] (CDMO) that serves both domestic and multinational pharmaceutical companies.<ref>{{Cite web |last=Mishra |first=Mihir |date=2023-04-30 |title=Akums Drugs plans IPO within 3 years |url=https://www.livemint.com/market/stock-market-news/akums-drugs-plans-ipo-in-2-3-years-to-give-exit-to-quadria-capital-expand-globally-and-double-net-sales-to-inr-10-000-crore-by-2028-11682877664726.html |access-date= |website=mint |language=en}}</ref><ref>{{Cite news |title=Akums Drugs and Pharmaceuticals Ltd. - Analyst Research Report |url=https://www.sbisecurities.in/fileserver/research/reports/Akums%20Drugs%20and%20Pharmaceuticals%20Limited_IPO%20Note.pdf |work=SBIsecurities}}</ref> The company was established in 2004 and became publicly listed on 6 August 2024.<ref name=":3">{{Cite web |last=Kumar Nahar |first=Pawan |date=2024-08-06 |title=Akums Drugs & Pharma shares list at 7% premium on BSE, NSE |url=https://www.businesstoday.in/markets/company-stock/story/akums-drugs-pharma-shares-list-at-7-premium-on-bse-nse-440279-2024-08-06 |access-date= |website=Business Today |language=en}}</ref>

== History ==
Akums was founded by Sanjeev Jain and Sandeep Jain in 2004, who currently serve as the managing directors of the company.<ref>{{Cite web |title=Akums Drugs and Pharmaceuticals Limited - Analyst Research Report |url=https://www.hdfcsec.com/hsl.docs/Akums%20Drugs%20and%20Pharmaceuticals%20Limited%20IPO%20Note-202407301109282134935.pdf |website=HDFCsec}}</ref> The company has 12 manufacturing facilities for various formulations and two facilities for producing [[Active ingredient|active pharmaceutical ingredients]] (APIs).<ref name=":0">{{Cite web |last= |first= |date=2023-12-05 |title=Akums buys new facility in Baddi to augment tablet output |url=https://www.thehindubusinessline.com/companies/akums-buys-new-facility-in-baddi-to-augment-tablet-output/article67606924.ece |access-date= |website=BusinessLine |language=en}}</ref> It produces tablets, capsules, soft gels, dry syrups, liquid orals, and other pharmaceutical products.<ref name=":1">{{Cite web |date=2023-09-23 |title=Quadria Capital-backed Akums, India's largest contract manufacturer of drugs, kicks off 2024 IPO plans |url=https://www.moneycontrol.com/news/business/quadria-capital-backed-akums-indias-largest-contract-manufacturer-of-drugs-kicks-off-2024-ipo-plans-11415811.html |access-date= |website=Moneycontrol |language=en}}</ref> Akums also operates four research and development (R&D) centers in India.<ref>{{Cite news |last=Somvanshi |first=Kiran |date=2024-07-30 |title=Akums Pharma placed at a vantage point in pharma growth |url=https://economictimes.indiatimes.com/markets/ipos/fpos/akums-pharma-placed-at-a-vantage-point-in-pharma-growth/articleshow/112122401.cms?from=mdr |access-date= |work=The Economic Times |issn=0013-0389}}</ref> In 2020, the company received an investment of Rs 500 crore from [[Quadria Capital]].<ref name=":1"/>

In April 2022, the company acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited.<ref>{{Cite web |last= |title=Akums acquires drug manufacturing facility from Ankur Drugs - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/akums-acquires-drug-manufacturing-facility-from-ankur-drugs/90844833 |access-date= |website=ETHealthworld.com {{!}} Pharma |language=en}}</ref> In May, the company received a license to manufacture and commercialize [[Bempedoic acid]], a drug used to [[Lipid-lowering agent|lower cholesterol]]. Two of the company's units in Haridwar were granted European GMP certification. One unit produces solid oral dosage forms, such as tablets and hard gelatin capsules, while the other manufactures large and small volume parenterals, including vials, ampoules, eye drops, and FFS formulations.<ref>{{Cite web |last= |title=Akums receives EU GMP approval for two manufacturing units in Haridwar - ET HealthWorld |url=https://health.economictimes.indiatimes.com/news/industry/akums-receives-eu-gmp-approval-for-two-manufacturing-units-in-haridwar/92702622 |access-date= |website=ETHealthworld.com |language=en}}</ref> In August 2024, the company went public with a listing on the [[Bombay Stock Exchange]] and the [[National Stock Exchange of India|National Stock Exchange]].<ref name=":3" /> In May 2025, Akums received a patent for an extended-release combination formulation of [[Doxylamine]] and [[Pyridoxine-dependent epilepsy|Pyridoxine]], indicated for the management of nausea and vomiting in pregnancy.<ref>{{Cite web |last=Singh |first=Anjali |date=May 5, 2025 |title=Akums secures patent for dual-action nausea drug for pregnant women |url=https://www.business-standard.com/companies/news/akums-secures-patent-for-dual-action-pregnancy-nausea-treatment-125050501037_1.html |archive-url=http://web.archive.org/web/20260224082025/https://www.business-standard.com/companies/news/akums-secures-patent-for-dual-action-pregnancy-nausea-treatment-125050501037_1.html |archive-date=2026-02-24 |access-date=2026-03-29 |website=www.business-standard.com |language=en-US}}</ref>

In July and September 2025, Akums received [[Good manufacturing practice]] (GMP) certifications for its manufacturing facilities in Haridwar, including from [[Brazilian Health Regulatory Agency]] and the [[Eurasian Economic Union]] (EAEU) for its hormonal therapy unit.<ref>{{Cite web |last= |first= |date=2025-07-28 |title=Akums secures Anvisa GMP certification for Haridwar plant to boost Brazil, LatAm exports |url=https://www.thehindubusinessline.com/companies/akums-receives-anvisa-gmp-certification-for-haridwar-sterile-manufacturing-facility/article69865758.ece |access-date=2026-04-22 |website=BusinessLine |language=en}}</ref><ref>{{Cite web |last= |title=Akums’ hormonal drug plant receives Eurasian Union nod |url=https://pharma.economictimes.indiatimes.com/news/pharma-industry/akums-receives-eaeu-gmp-certification-for-hormonal-drug-manufacturing/123782708 |access-date=2026-04-22 |website=ETPharma.com |language=en}}</ref> In January 2026, two of its facilities in Haridwar, Uttarakhand, received European Union GMP certification issued by the Bulgarian Drug Agency (BDA).<ref>{{Cite web |last= |title=Akums secures EU GMP certificate for two manufacturing units |url=https://pharma.economictimes.indiatimes.com/news/regulatory-update/akums-secures-eu-gmp-certificate-for-two-manufacturing-units/127283745 |access-date=2026-04-22 |website=ETPharma.com |language=en}}</ref>

In November 2025, a 20-year patent for Dual Release Gastro-Resistant Composition effective from 19 November 2022, was granted to the company under the [[Patent Act of 1790|Patents Act, 1970]].<ref>{{Cite web |title=Akums Drugs gets 20- year patent for |url=https://www.indianpharmapost.com/news/akums-drugs-gets-20-year-patent-for-dual-release-gastro-resistant-composition-18144 |access-date=2026-04-22 |website=indianpharmapost}}</ref>

In February 2026, it received approval from the United Kingdom’s [[Medicines and Healthcare products Regulatory Agency]] (MHRA) to market rivaroxaban, an anticoagulant, in the country.<ref>{{Cite web |last= |title=Akums secures blood thinner Rivaroxaban marketing approval in UK |url=https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/akums-secures-blood-thinner-rivaroxaban-marketing-approval-in-uk/128255271 |access-date=2026-04-22 |website=ETPharma.com |language=en}}</ref>

== Partnerships ==
In October 2024, Akums partnered with Microcore Research to use [[Eggshell membrane|natural eggshell membrane]] (NESM) in the development of dietary supplements for joint and connective tissue health.<ref>{{Cite web |last= |title=Akums, Microcore Research enter JV to develop NESM dietary supplements - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/akums-microcore-research-enter-jv-to-develop-nesm-dietary-supplements/95197137 |access-date= |website=ETHealthworld.com {{!}} Pharma |language=en}}</ref>

In November 2023, Akums entered into a MoU with [[Delhi Pharmaceutical Sciences and Research University]] to collaborate on research and product development for patients in India.<ref>{{Cite web |date=2023-11-10 |title=DPSRU inks MoU with Akums Drugs to enhance pharma education and research |url=https://www.hindustantimes.com/education/news/dpsru-inks-mou-with-akums-drugs-to-enhance-pharma-education-and-research-101699011694592.html |access-date= |website=Hindustan Times |language=en}}</ref>

In October 2024, the company entered into a License and Distribution Agreement with Triple Hair Inc., a company based in New Brunswick, Canada. The agreement involved the licensing of a patented alopecia treatment from Triple Hair Group.<ref>{{Cite web |last=Ghosh |first=Anupama |date=2024-10-16 |title=Akums Drugs Stocks: Secures exclusive rights to Triple Hair's products in India |url=https://www.thehindubusinessline.com/markets/stock-markets/akums-drugs-secures-exclusive-rights-to-triple-hairs-products-in-india-stocks-shoot-up/article68760156.ece |access-date=2025-03-24 |website=BusinessLine |language=en}}</ref>

In November 2024, Akums partnered with Caregen to introduce specialty nutraceuticals and cosmeceuticals in India.<ref>{{Cite web |date=2024-11-29 |title=Akums partners with Caregen to launch Specialty Nutraceuticals and Differentiated Cosmeceuticals in India |url=https://www.financialexpress.com/business/healthcare-akums-partners-with-caregen-to-launch-specialty-nutraceuticals-and-differentiated-cosmeceuticals-in-india-3679912/ |access-date=2025-03-24 |website=Financialexpress |language=en}}</ref> During the same month, the company partnered with Jagdale to market ready-to-drink (RTD) nutritional beverages in India.<ref>{{Cite web |last= |first= |date=2024-11-27 |title=Akums, Jagdale partner to manufacture aseptic carton packing for ready-to-drink nutritional beverages |url=https://www.expresspharma.in/akums-jagdale-partner-to-manufacture-aseptic-carton-packing-for-ready-to-drink-nutritional-beverages/ |access-date=2025-03-24 |website=Express Pharma |language=en-US}}</ref>

In December 2024, Akums Drugs & Pharmaceuticals signed a long-term contract worth approximately ₹1,760 crore with a pharmaceutical company to manufacture and supply pharmaceutical formulations in the European market.<ref>{{Cite news |last=Pilla |first=Viswanath |date=2024-12-26 |title=Akums enters into Rs 1750 crore contract to supply pharma products to Europe |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/akums-enters-into-rs-1750-crore-contract-to-supply-pharma-products-to-europe/articleshow/116684376.cms?from=mdr |access-date=2025-03-24 |work=The Economic Times |issn=0013-0389}}</ref><ref>{{Cite web |last= |first= |title=Akums Group signs 200 million euro deal for European market expansion |url=https://www.business-standard.com/companies/news/akums-group-signs-200-million-euro-deal-for-european-market-expansion-124122600849_1.html |archive-url=https://web.archive.org/web/20241227101958/https://www.business-standard.com/companies/news/akums-group-signs-200-million-euro-deal-for-european-market-expansion-124122600849_1.html |archive-date=27 December 2024 |access-date=2025-03-24 |website=www.business-standard.com |language=en-US |url-status=live }}</ref>

In March 2025, the company signed a memorandum of understanding with [[National Institute of Food Technology Entrepreneurship and Management|National Institute of Food Technology Entrepreneurship and Management Thanjavur]] for collaboration on internships and research projects focused on nutraceutical product development and process improvement.<ref>{{Cite web |last= |title=Akums, NIFTEM ink MoU to upskill students and advance nutraceuticals portfolio |url=https://pharma.economictimes.indiatimes.com/news/pharma-industry/akums-niftem-ink-mou-to-upskill-students-and-advance-nutraceuticals-portfolio/118678635 |access-date=2026-03-29 |website=ETPharma.com |language=en}}</ref> In April 2025, it signed a memorandum of agreement with [[Tamil Nadu Agricultural University]] for collaboration on research and development in pharmaceutical formulations.<ref>{{Cite web |last= |first= |date=2025-04-24 |title=Akums Drugs signs MoA with TNAU to boost R&D in agri-based pharma formulations |url=https://www.thehindubusinessline.com/economy/agri-business/akums-drugs-signs-moa-with-tnau-to-boost-rd-in-agri-based-pharma-formulations/article69486653.ece |access-date=2026-03-29 |website=BusinessLine |language=en}}</ref>

In August 2025, Akums and the Government of the Republic of [[Zambia]] announced a partnership to establish a pharmaceutical manufacturing facility in Zambia for the production of generic medicines, with construction of the facility subsequently initiated.<ref>{{Cite web |last= |date=August 24, 2025 |title=Akums to set up new manufacturing plant in Zambia via JV with local govt |url=https://pharma.economictimes.indiatimes.com/news/pharma-industry/akums-drugs-and-pharmaceuticals-announces-new-manufacturing-plant-in-zambia/123484759 |access-date=2026-04-22 |website=ETPharma.com |language=en}}</ref><ref>{{Cite web |last= |date=October 28, 2025 |title=Akums breaks ground in Zambia for new manufacturing plant |url=https://pharma.economictimes.indiatimes.com/news/pharma-industry/akums-breaks-ground-in-zambia-for-new-manufacturing-plant/124869185 |access-date=2026-04-22 |website=ETPharma.com |language=en}}</ref>

In December 2025, Akums and [[Sharda University]] signed a memorandum of understanding to collaborate on pharmaceutical research, technology transfer, skill development, internships, and joint projects.<ref>{{Cite web |last=Jyoti |first=Archana |date=2025-12-30 |title=Akums Drugs & Pharma Partners With Sharda University To Deepen Industry–Academia Collaboration |url=https://www.outlookindia.com/healthcare-spotlight/akums-drugs-pharma-partners-with-sharda-university-to-deepen-industryacademia-collaboration |access-date=2026-04-22 |website=Outlook India |language=en}}</ref>

== Product development ==
In August 2023, Akums launched a formulation for managing [[Type 2 diabetes|Type-2 Diabetes]] in elderly patients,<ref>{{Cite web |last= |first= |date=2023-08-10 |title=Pharma firm launches new treatment for Type-2 diabetes among elderly |url=https://www.newindianexpress.com/cities/delhi/2023/Aug/26/pharma-firm-launches-new-treatment-for-type-2-diabetes-among-elderly-2608926.html |access-date= |website=The New Indian Express |language=en}}</ref> which combines multiple medications to help control blood sugar levels.<ref>{{Cite web |title=DCGI Approves Akums Pharma To Launch Diabetes Drug Lobeglitazone In India |url=https://bwwellbeingworld.com/article/dcgi-approves-akums-pharma-to-launch-diabetes-drug-lobeglitazone-in-india-464559 |access-date= |website=BW Wellbeing |language=en}}</ref> On 15 September 2023, it introduced a fixed-dose combination capsule of Tamsulosin and Tadalafil, containing Tamsulosin 0.4 mg and Tadalafil 2.5 mg.<ref name=":2">{{Cite web |last= |title=Akums introduces Tamsulosin + Tadalafil capsule — to the Indian market - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/akums-introduces-tamsulosin-tadalafil-capsule-to-the-indian-market/103692638 |access-date= |website=ETHealthworld.com {{!}} Pharma |language=en}}</ref> The company also began manufacturing nutraceutical gummies.<ref>{{Cite web |date=2023-08-01 |title=Akums to diversify its portfolio for innovative gummy formulations |url=https://www.financialexpress.com/life/akums-to-diversify-its-portfolio-for-innovative-gummy-formulations-3194313/ |access-date= |website=Financialexpress |language=en}}</ref><ref>{{Cite web |last= |title=Akums announces entry into nutraceutical gummies segment - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/akums-announces-entry-into-nutraceutical-gummies-segment/98361976 |access-date= |website=ETHealthworld.com {{!}} Pharma |language=en}}</ref>

In December 2023, Akums acquired a formulation facility in [[Baddi|Baddi, Himachal Pradesh]],<ref name=":0" /> and announced the launch of Doxylamine and Pyridoxine extended-release tablets, which are approved by the [[Central Drugs Standard Control Organisation]] (CDSCO) in India and the [[Food and Drug Administration|United States Food and Drug Administration]] (US FDA).<ref>{{Cite web |last= |title=Akums launches Doxylamine + Pyridoxine extended-release tablets - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/akums-launches-doxylamine-pyridoxine-extended-release-tablets/106155230 |access-date= |website=ETHealthworld.com {{!}} Pharma |language=en}}</ref>

In 2024, the company launched several products, including Lasmiditan tablets,<ref>{{Cite web |last= |first= |date=2024-01-05 |title=Akums launches Lasmiditan Tablet for migraine management |url=https://www.expresspharma.in/akums-launches-lasmiditan-tablet-for-migraine-management/ |access-date= |website=Express Pharma |language=en-US}}</ref> [[nasal spray]]s,<ref>{{Cite web |last= |title=Akums Drugs and Pharmaceuticals unveils nasal sprays - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/akums-drugs-and-pharmaceuticals-unveils-nasal-sprays/107461977 |access-date= |website=ETHealthworld.com |language=en}}</ref> Hydroxyurea for sickle cell anemia,<ref>{{Cite web |date=2024-03-17 |title=Akums launches sickle cell anaemia drug for 1% of global price |url=https://indianexpress.com/article/india/akums-launches-sickle-cell-anaemia-drug-for-1-of-global-price-9218512/ |access-date= |website=The Indian Express |language=en}}</ref> and a fixed-dose combination of Amlodipine, Telmisartan, and Metoprolol (extended-release) tablets for hypertension.<ref>{{Cite web |last= |title=Akums launches Rabeprazole + Levosulpiride SR capsules - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/akums-launches-rabeprazole-levosulpiride-sr-capsules/110907838 |access-date= |website=ETHealthworld.com |language=en}}</ref><ref>{{Cite web |last= |title=Akums introduces Amlodipine, Telmisartan & Metoprolol (ER) film coated tablets for hypertension management - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/akums-introduces-amlodipine-telmisartan-metoprolol-er-film-coated-tablets-for-hypertension-management/109884932 |access-date= |website=ETHealthworld.com {{!}} Pharma |language=en}}</ref>

In June 2024, Akums launched Rabeprazole + Levosulpiride SR Capsules as part of its new gastrointestinal formulations in India for the treatment of digestive health conditions.<ref>{{Cite web |last=www.ETHealthworld.com |title=Akums launches anti-reflux antacid - sodium alginate + potassium bicarbonate chewable tablet - ET HealthWorld {{!}} Pharma |url=https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/akums-launches-anti-reflux-antacid-sodium-alginate-potassium-bicarbonate-chewable-tablet/111137635 |access-date=2025-03-24 |website=ETHealthworld.com {{!}} Pharma |language=en}}</ref><ref>{{Cite web |date=2024-06-10 |title=Akums launches novel formulations for patients with gastrointestinal disorders in India |url=https://www.financialexpress.com/business/healthcare-akums-launches-novel-formulations-for-patients-with-gastrointestinal-disorders-in-india-3520238/ |access-date=2025-03-24 |website=Financialexpress |language=en}}</ref>

In January 2025, Akums has begun developing a new facility for lyophilized and sterile dosage manufacturing, focusing on injectables and biologics.<ref>{{Cite news |date=2 January 2025 |title=Akums announces new facility for lyophilized, sterile dosage manufacturing |url=https://www.business-standard.com/companies/news/akums-announces-new-facility-for-lyophilized-sterile-dosage-manufacturing-125010200778_1.html |work=business-standard}}</ref> In February 2025, the company announced the launch of a combination therapy containing Dapagliflozin and Pioglitazone, indicated for the management of Type 2 Diabetes.<ref>{{Cite web |last= |title=Akums launches drug combo for Type-2 Diabetes |url=https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/akums-launches-drug-combo-for-type-2-diabetes/117884021 |access-date=2026-03-29 |website=ETPharma.com |language=en}}</ref> In April 2025, Akums announced the launch of a combination therapy containing [[Ripasudil]] and [[Timolol]], indicated for the management of [[Glaucoma]].<ref>{{Cite web |date=2025-04-01 |title=Akums launches combination formulation for glaucoma and ocular hypertension treatment |url=https://www.financialexpress.com/business/healthcare-akums-launches-combination-formulation-for-glaucoma-and-ocular-hypertension-treatment-3795130/ |access-date=2026-03-29 |website=The Financial Express |language=en}}</ref>

In December 2025, Akums introduced an extended-release formulation of gabapentin for the management of [[postherpetic neuralgia]] (PHN), a chronic neuropathic pain condition associated with shingles.<ref>{{Cite web |last= |title=Akums launches enhanced Gabapentin ER for PHN management |url=https://pharma.economictimes.indiatimes.com/news/pharma-industry/akums-introduces-advanced-gabapentin-er-tablets-for-effective-phn-management/125972927 |access-date=2026-04-22 |website=ETPharma.com |language=en}}</ref>

== See also ==

* [[Pharmaceutical companies]]
* [[Pharmaceutical industry in India]]

== References ==
{{reflist}}

== External links ==
* {{Official website|https://akumslifesciences.com/}}

[[Category:2004 establishments in Delhi]]
[[Category:Pharmaceutical companies of India]]
[[Category:Health care companies of India]]
[[Category:Pharmaceutical companies established in 2004]]
[[Category:Indian companies established in 2004]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Companies based in Delhi]]
[[Category:Contract development and manufacturing organizations]]

Akums Drugs and Pharmaceuticals - Revision history

Ieagle123 at 16:30, 6 May 2026